X4 Pharmaceuticals
One Broadway, 14th Floor
Cambridge
Massachusetts
02142
United States
Website: http://www.x4pharma.com/
234 articles about X4 Pharmaceuticals
-
X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial
10/19/2021
X4 Pharmaceuticals, Inc. announced the appointment of Françoise de Craecker to the company’s Board of Directors and the recent hiring of Karolyn Park to the newly created role of Vice President, U.S. Commercial, significantly strengthening the company’s depth and breadth of commercial leadership experience.
-
Patients and patient organizations, which have detailed insights in the natural history of a rare disease, should be integral, too.
-
X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome
10/4/2021
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), announced today that it has completed enrollment in the ongoing pivotal Phase 3 clinical trial of its lead candidate, mavorixafor, in the treatment of patients with genetically confirmed WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, a primary immunodeficiency caused by gain-of-function mutations in the CXCR4 gene.
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021
10/1/2021
X4 Pharmaceuticals, Inc. announced that, on September 30, 2021, the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
-
X4 Pharmaceuticals to Participate in Upcoming Investor Conferences
9/15/2021
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit and participate in a fireside chat at the Cantor Global Healthcare Conference.
-
X4 Pharmaceuticals Promotes Mary DiBiase, Ph.D. to Chief Operating Officer
9/8/2021
X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, announced the promotion of Mary DiBiase, Ph.D. to the newly created position of Chief Operating Officer.
-
X4 Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
9/1/2021
X4 Pharmaceuticals, Inc. today announced that management will conduct one-on-one investor meetings at the Citi 16th Annual BioPharma Conference and participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference.
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2021
9/1/2021
X4 Pharmaceuticals, Inc. announced that, on August 31, 2021, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
-
Clinical Catch-Up: August 2-6
8/9/2021
It was a busy week for clinical trial announcements. Take a look. -
X4 Pharmaceuticals to Participate at Canaccord Genuity’s Virtual 41st Annual Growth Conference
8/4/2021
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at Canaccord Genuity’s 41st Annual Growth Conference on Thursday, August 12, 2021.
-
X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter Financial Results
8/3/2021
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today reported financial results for the second quarter and six months ended June 30, 2021.
-
X4 Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 3, 2021
7/22/2021
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the second quarter ended June 30, 2021, and provide an update on recent business highlights, on August 3, 2021.
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2021
7/1/2021
X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on June 30, 2021, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
-
X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021
6/11/2021
X4 Pharmaceuticals, Inc. announced positive preliminary efficacy and safety data from its ongoing Phase 1b clinical trial of its lead candidate mavorixafor, in combination with ibrutinib, in Waldenström’s macroglobulinemia patients with both MYD88 and CXCR4 mutations.
-
X4 Pharmaceuticals to Host Conference Call and Webcast to Present Initial Efficacy and Safety Data from EHA 2021 Poster on Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia
5/26/2021
X4 Pharmaceuticals, Inc. announced it will be hosting a conference call and webcast to present and discuss initial efficacy and safety data from the ongoing Phase 1b clinical trial of its lead clinical candidate, mavorixafor, in combination with ibrutinib, in Waldenström’s Macroglobulinemia patients with MYD88 and CXCR4 mutations.
-
X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences
5/17/2021
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit and present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit.
-
X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract
5/12/2021
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today disclosed the first efficacy and safety data from a small cohort of patients in its ongoing Phase 1b clinical trial of its lead candidate mavorixafor
-
X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
5/6/2021
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today reported financial results for the first quarter ended March 31, 2021
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2021
5/4/2021
X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on April 30, 2021, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.